Elevance Health (NYSE:ELV) Releases FY 2026 Earnings Guidance

Elevance Health (NYSE:ELV) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 26.750- for the period, compared to the consensus earnings per share estimate of 26.910. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ELV shares. UBS Group boosted their price objective on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Mizuho increased their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a report on Monday. Jefferies Financial Group lowered their price objective on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Finally, Robert W. Baird raised their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $416.11.

Elevance Health Trading Down 4.7%

NYSE:ELV opened at $404.33 on Thursday. The company has a fifty day moving average of $362.40 and a 200 day moving average of $343.89. Elevance Health has a 52 week low of $273.71 and a 52 week high of $426.98. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $87.81 billion, a P/E ratio of 17.20, a P/E/G ratio of 2.40 and a beta of 0.67.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the company earned $11.97 earnings per share. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts predict that Elevance Health will post 26.94 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s payout ratio is presently 29.26%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Pettinga Financial Advisors LLC grew its position in Elevance Health by 4.8% during the fourth quarter. Pettinga Financial Advisors LLC now owns 812 shares of the company’s stock valued at $285,000 after buying an additional 37 shares during the period. Foresight Global Investors Inc. grew its holdings in Elevance Health by 5.6% during the fourth quarter. Foresight Global Investors Inc. now owns 865 shares of the company’s stock valued at $303,000 after purchasing an additional 46 shares during the period. UMB Bank n.a. lifted its holdings in Elevance Health by 2.6% in the 4th quarter. UMB Bank n.a. now owns 2,113 shares of the company’s stock worth $741,000 after purchasing an additional 53 shares in the last quarter. HM Payson & Co. lifted its holdings in shares of Elevance Health by 15.0% in the fourth quarter. HM Payson & Co. now owns 437 shares of the company’s stock worth $153,000 after buying an additional 57 shares in the last quarter. Finally, CreativeOne Wealth LLC boosted its holdings in shares of Elevance Health by 4.4% during the 3rd quarter. CreativeOne Wealth LLC now owns 1,569 shares of the company’s stock valued at $507,000 after purchasing an additional 66 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.